Biocartis
Biocartis, AstraZeneca Ink Companion Diagnostic Pact
The agreement includes obtaining US regulatory clearance of a companion diagnostic for Tagrisso, which is used to treat NSCLC patients who carry specific mutations.
Biocartis Nabs CE Mark for Lung Cancer Test
The firm's panel detects ALK, ROS1, RET, and METex14 skipping, actionable targets relevant in non-small cell lung cancer, in three hours.Â
Biocartis, SkylineDx Partner to Develop Melanoma Nodal Metastasis Risk Test
The Belgian molecular diagnostics firm also reported a 70 percent year-over-year increase in commercial cartridge volumes in the first quarter.
Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement
The partners will extend the lung cancer biomarker study to countries in and outside Europe, and see if liquid biopsy could offer benefits to tissue-based testing.
Comparison of KRAS Liquid Biopsy Kits Confirms Differences at Low Mutant Allele Fraction
Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.